Topics

RESILIENT study tests benefit of ETA guided treatments for patients with advanced refractory cancers

14:29 EDT 11 Oct 2019 | News-Medical.net

RESILIENT was a single arm, open label, phase II/III study to test if label agnostic therapy regimens guided by Encyclopedic Tumor Analysis can offer meaningful clinical benefit for patients with relapsed refractory metastatic malignancies.

Original Article: RESILIENT study tests benefit of ETA guided treatments for patients with advanced refractory cancers

NEXT ARTICLE

More From BioPortfolio on "RESILIENT study tests benefit of ETA guided treatments for patients with advanced refractory cancers"

Quick Search

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...